Discover how dynamic BH3 profiling can predict responses in lung cancer patients to ALK inhibitors, enhancing personalized ...

"For example, the drug Venetoclax — an inhibitor of the anti-apoptotic protein BCL-2 — has been successfully approved for clinical use. In parallel, inhibitors of other anti-apoptotic proteins ...